甲泼尼龙与孟鲁司特钠联合治疗儿童复发性过敏性紫癜的效果研究  

Study on the efficacy of methylprednisolone combined with montelukast sodium in the treatment of recurrent Henoch-Schonlein purpura in children

作　　者：张颖 ZHANG Ying(First Department of Pediatrics,Jinxiang County People's Hospital,Jining 272200,China)

机构地区：[1]金乡县人民医院儿一科,272200

出　　处：《中国现代药物应用》2024年第8期24-28,共5页Chinese Journal of Modern Drug Application

摘　　要：目的分析儿童复发性过敏性紫癜(HSP)患儿接受甲泼尼龙与孟鲁司特钠联合治疗的效果。方法60例儿童复发性HSP患儿,使用随机数字表法分为对照组和研究组,每组30例。对照组采用孟鲁司特钠治疗,研究组在对照组基础上联用甲泼尼龙琥珀酸钠治疗。比较两组患儿临床疗效、症状改善时间、不良反应发生情况、复发情况以及治疗前后的免疫球蛋白指标[免疫球蛋白(Ig)M、IgA]、炎症因子[白细胞介素-6(IL-6)、C反应蛋白(CRP)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)]。结果与对照组总有效率(73.33%)相比,研究组(96.67%)较高,差异有统计学意义(P<0.05)。研究组患儿的消化道症状缓解时间、关节症状缓解时间、皮肤紫癜消失时间分别为(3.62±0.56)、(3.80±0.70)、(7.22±1.02)d,对照组患儿的消化道症状缓解时间、关节症状缓解时间、皮肤紫癜消失时间分别为(5.02±0.50)、(5.22±0.75)、(9.20±1.56)d。与对照组结果相比,研究组消化道症状缓解时间、关节症状缓解时间、皮肤紫癜消失时间更短,差异有统计学意义(P<0.05)。治疗后,研究组IgM、IgA水平分别为(1.55±0.25)、(5.20±0.85)g/L,对照组IgM、IgA水平分别为(2.10±0.34)、(7.35±1.02)g/L。与对照组结果相比,研究组IgM与IgA水平更低,差异有统计学意义(P<0.05)。治疗后,研究组患儿IL-6、CRP、PCT、TNF-α水平分别为(4.30±0.40)μg/L、(4.32±1.20)mg/L、(0.32±0.13)ng/ml、(3.23±1.00)ng/L,对照组患儿IL-6、CRP、PCT、TNF-α水平分别为(4.80±0.30)μg/L、(5.75±1.80)mg/L、(0.47±0.15)ng/ml、(5.75±1.20)ng/L。与对照组结果相比,研究组IL-6、CRP、PCT与TNF-α水平更低,差异有统计学意义(P<0.05)。两组不良反应发生率比较,结果无显著差异(P>0.05)。随访6个月,与对照组复发率(30.00%)相比,研究组的复发率(6.67%)更低,差异有统计学意义(P<0.05)。结论甲泼尼龙与孟鲁司特钠联合治疗儿童复发性HSP效果确切,能�Objective To analyze the effect of methylprednisolone combined with montelukast sodium in the treatment of recurrent Henoch-Schonlein purpura(HSP)in children.Methods 60 children with recurrent HSP were divided into a control group and a study group using random number table,with 30 cases in each group.The control group was treated with montelukast sodium,and the study group was combined with methylprednisolone sodium succinate based on the control group.Patients in both groups were compared in terms of clinical efficacy,symptom improvement time,occurrence of adverse reactions,recurrence,and immunoglobulin indexes[immunoglobulin(Ig)M,IgA],inflammatory factors[interleukin-6(IL-6),C-reactive protein(CRP),procalcitonin(PCT),tumor necrosis factor-α(TNF-α)]before and after treatment.Results The total effective rate of the study group(96.67%)was higher than that of the control group(73.33%),and the difference was statistically significant(P<0.05).In the study group,the relief time of gastrointestinal symptoms,joint symptoms and skin purpura were(3.62±0.56),(3.80±0.70)and(7.22±1.02)d;in the control group,the relief time of gastrointestinal symptoms,joint symptoms and skin purpura were(5.02±0.50),(5.22±0.75)and(9.20±1.56)d.Compared with the control group,the relief time of gastrointestinal symptoms,joint symptoms and skin purpura in the study group was shorter,and the difference was statistically significant(P<0.05).After treatment,IgM and IgA levels in the study group were(1.55±0.25)and(5.20±0.85)g/L,while those in the control group were(2.10±0.34)and(7.35±1.02)g/L.Compared with the control group,the study group showed lower levels of IgM and IgA,and the difference was statistically significant(P<0.05).After treatment,the levels of IL-6,CRP,PCT and TNF-αin the study group were(4.30±0.40)μg/L,(4.32±1.20)mg/L,(0.32±0.13)ng/ml and(3.23±1.00)ng/L,and those in the control group were(4.80±0.30)μg/L,(5.75±1.80)mg/L,(0.47±0.15)ng/ml and(5.75±1.20)ng/L.Compared with the control group,the study group showed

关 键 词：甲泼尼龙 孟鲁司特钠 儿童 过敏性紫癜 复发 

分 类 号：R725.5[医药卫生—儿科]